U.S. President Donald Trump signed an executive order on Monday, August 10, calling for childhood vaccines to be administered at separate medical visits whenever possible and for the combined measles, mumps and rubella vaccine to be replaced by three individual products once they become available. The Associated Press reported that the directive asks federal health officials to revise recommendations, while state governments retain authority over school vaccination requirements.
The order arrives as children return to classrooms and the United States confronts its worst measles activity in more than three decades. AP cited Centers for Disease Control and Prevention data showing more than 2,318 cases during 2026 by late July. Health specialists warned that adding appointments could leave children unprotected for longer and increase the likelihood that families miss later doses.
Trump and administration officials said separating products and visits would give parents more choice over timing and could improve confidence and uptake. The directive also calls for further vaccine research. However, separate measles, mumps and rubella vaccines are not currently available in the United States, meaning manufacturers would need to develop products, conduct clinical trials and secure regulatory approval before that element could take effect.
The CDC's published guidance says there is no demonstrated benefit from splitting the combined MMR vaccine into three injections. Its current schedule calls for a first MMR dose at 12 to 15 months and a second at four to six years, with an earlier second dose possible when needed. Federal health information also says spreading vaccinations out provides no benefit and that the recommended timing protects children before exposure.
The American Academy of Pediatrics said no new evidence justifies major changes and warned that the order could create dangerous delays. Republican Senator Bill Cassidy of Louisiana, a physician who chairs the Senate health committee, also opposed the measure, saying separate products would require more injections for the same protection. The administration argues that greater flexibility will answer parental concerns.
Implementation remains uncertain because a federal judge previously blocked administration changes to childhood vaccine recommendations, and the new order does not itself rewrite state school rules. Insurers have not clarified whether they would cover additional visits, while federal agencies must determine how to act on the directive. Pediatric groups are continuing to recommend their evidence-based schedule as the legal, regulatory and manufacturing questions move forward.
Comments